PARIS--(Marketwire - Sep 10, 2012) -  Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the endomicroscopy market and developer of Cellvizio® imaging, the fastest way to see cancer, today announced the launch of the first dual color endomicroscopy imaging system, the Cellvizio® Dual Band. The Cellvizio Dual Band incorporates color into the state-of-the-art molecular imaging system that will allow researchers to visualize both structural and functional information of tissue inside animals' bodies in real time. The company unveiled the new product at the World Molecular Imaging Congress (WMIC), which took place in Dublin from September 5 to 8.

"With the Cellvizio Dual Band, we can now offer laboratories additional information about live, in-vivo cellular interaction that will provide researchers with the ability to observe functional and morphological activity as it happens. The ability to see and monitor an animal's internal physiological processes at the cellular level helps researchers gain new understanding of the root causes of disease and disorders," said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies. "This represents an important milestone for the company and demonstrates our ongoing commitment to remain at the forefront of innovation in the imaging market."

In vivo small animal imaging is used in pre-clinical research at academic institutions and biotechnological and pharmaceutical companies. Such experiments play a key role in neuroscience and cancer research. Other applications of Cellvizio Dual Band include stem cell research, immunology or drug discovery.

Separately at WMIC, researchers presented the results of four studies. During an oral presentation on September 7, researchers from the MRC Centre for Inflammation Research at the University of Edinburgh in Scotland discussed the development and clinical application of an imaging agent that would allow them to stratify acute lung injury with Cellvizio Dual Band imaging in an intensive care setting, an important potential market for Mauna Kea Technologies. Three posters explored improved in vivo imaging of individual cells in mice; use of Cellvizio LAB to improve lung cancer detection; and use of the technology for real-time monitoring of drug delivery mechanisms being tested for use in personalized medicine, respectively.

Click on the link below to see the Cellvizio Dual Band video:

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information on Mauna Kea Technologies, visit

Contact Information:

United States

Lazar Partners Ltd.
Erich Sandoval
Tel: +1 917 497 2867

Mauna Kea Technologies
Alexander Bryson
Marketing Communications and Brand Manager
Tel: +33 (0) 1 70 08 09 92

France and Europe

Caroline Carmagnol
Tel: + 33 1 42 68 86 43 / + 33 6 64 18 99 59

Communication financiere et relations investisseurs
Pierre Laurent / Florent Alba
Tel: +33 1 44 71 94 94